Preclinical and clinical investigations showed that IL6-JAK-STAT3 pathway inhibition has therapeutic benefits in cancer and that STAT3 inhibition inhibits the growth of glioma cells (Shen et al., 2009; Johnson et al., 2018). Here, STAT3 is linked to cancer.